Menu


Visitors To Our Site
GERMANY
  22.4%
UNITED STATES
  16.1%
RUSSIAN FEDERATION
  7.9%
ROMANIA
  7.0%
UNITED KINGDOM
  5.7%
NETHERLANDS
  5.6%
CZECH REPUBLIC
  4.5%
POLAND
  4.3%
SWEDEN
  3.3%
ITALY
  3.2%
CHINA
  3.0%
SPAIN
  2.3%
HUNGARY
  1.4%
LATVIA
  1.2%
FRANCE
  1.2%
 home > not required


Sponsors of The Power of Patient Voice 2011




Gold



Silver



Bronze



Abbott Molecular
Abbott Molecular provides physicians with critical information based on the early detection of pathogens and subtle changes in patients' genes and chromosomes, allowing for earlier diagnosis, selection of appropriate therapies and monitoring of disease progression. The product portfolio includes instruments and reagents used to conduct sophisticated analysis of patient DNA and RNA through Real-Time PCR, FISH and Sequencing Technologies.

The European School of Encology (ESO)
The European School of Oncology (ESO) was founded in 1982, with the aim of contributing to the reduction of deaths from cancer due to late diagnosis and/or inadequate treatment.  ESO's mission is reflected in its motto “Learning to Care”, which stresses the concept of studying and learning and also of caring for the patient in a global sense.  By improving the skills of all health professionals dealing with cancer patients, ESO shortens the length of time needed to transfer knowledge from research centres to daily practice, combining advanced technology with humanism in care.

Roche
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2010, Roche had over 80'000 employees worldwide and invested over 9 billion Swiss francs in R&D. For more information: www.roche.com

Sirtex Medical Europe GmbH
Our innovative technology, SIR-Spheres® microspheres, was approved in 2002 for use in the treatment of unresectable liver tumours within the European Union under a CE Mark. SIR-Spheres microspheres are presently used to treat a variety of unresectable liver metastases as well as in hepatocellular carcinoma at more than 60 European institutions.® SIR-Spheres is a Registered Trademark of Sirtex SIR-Spheres Pty Ltd

Merck Serono Oncology Profile
Merck Serono, a division of Merck KGaA, focuses its oncology research on the development of novel therapies that target the tumor cell directly, the tumor environment or the immune system, including the monoclonal antibody Erbitux® which specifically blocks the epidermal growth factor receptor (EGFR), and the development compounds Stimuvax® (cancer immunotherapy) and cilengitide (integrin inhibitor).

Epigenomics
Epigenomics is a molecular diagnostics company developing and commercializing proprietary products for cancer which enable doctors to diagnose cancer earlier and more accurately, leading to improved outcomes for patients. Epigenomics' lead product, Epi proColon® is a blood-based test for early detection of colorectal cancer, which is marketed in Europe and in development for the US.

Olympus

OLYMPUS manufactures a complete range of medical and surgical endoscopes, EndoTherapy products, and comprehensive systems solutions for numerous medical applications. OLYMPUS demonstrates technology leadership with the following core products

•    EXERA II endoscopy system with HDTV (1080) high definition imaging technologies like NBI

•    ScopeGuide system – Olympus' unique colonoscopy navigation device

•    The EU-ME1 all-in-one ultrasound processor for electronic and mechanical scanning

•    EnteroPro System - consisting of the Single-Ballon-Enteroscope, ET instruments, and EndoCapsule, allowing full access to the small bowel.
Latest News
Newly Identified Stem Cells May Hold Clues to Colon Cancer
Vanderbilt-Ingram Cancer Center researchers have identified a new population......
read more right arrow

Study Establishes Safety and Clinical Benefit of SIR-Spheres® microspheres in Treating Metastatic Liver Tumors in Patients who Failed Systemic Chemotherapy
SIR-Spheres® microspheres are safe and provide clinical benefit for......
read more right arrow

BSD Featured at Annual Meeting of the German Cancer Society
BSD Medical Corporation (NASDAQ:BSDM) (Company or BSD) (www.BSDMedical.com), a......
read more right arrow

The Anti Colon Cancer Diet
8 Steps to Naturally Reduce Your Risk of Colon......
read more right arrow

Colorectal Cancer For Under 50s On The Rise
Whilst colorectal cancer cases are generally on the decline......
read more right arrow

Anti-cancer 'super' aspirin under development
Studies in mice show the compound to be effective......
read more right arrow


Facebook

Read our Newsletter here >>
Registration No: 5314195 Registered Office: 92 Palatine Road, London N16 8ST.